LN Future (LNFI) H1 2025 earnings summary

Executive summary

• Completed strategic review led to sale of operational business and brand to Addeira Pharmaceuticals AB for SEK 13.3 million, leaving no ongoing operations.

• Company name changed to LN Future Invest AB; focus now on exploring strategic alternatives, including a potential reverse acquisition.

• Leadership changes followed the transaction, with the CEO and a board member stepping down and the CFO appointed as new CEO.

Financial highlights

• Net sales for H1 2025 were SEK 11,319k, down 15.7% year-over-year; total operating income was SEK 12,730k.

• EBIT for H1 2025 was SEK -957k, a deterioration from SEK -231k in H1 2024.

• Gross margin remained stable at 54% year-over-year.

• Cash flow for H1 2025 was SEK -1,923k; cash position at June 30, 2025, was SEK 503k, with SEK 13.3 million added post-period from the business sale.

• Earnings per share for H1 2025 was SEK -0.09, compared to SEK -0.02 in H1 2024.

Outlook and guidance

• With no operational business post-sale, the board will evaluate strategic alternatives, including a reverse acquisition or, if none are found, voluntary liquidation and distribution of cash to shareholders.